血脂康片联合氯吡格雷治疗不稳定型心绞痛伴动脉粥样硬化的临床疗效及安全性

摘要

Objective To analyze the clinical effect and safety of xuezhikang tablets combined with clopidogrel in treating unstable angina pectoris patients complicated with atherosclerosis.Methods A total of 160 unstable angina pectoris patients complicated with atherosclerosis were selected in the 215th Hospital of Nuclear Industry of Shaanxi Province from June 2014 to June 2015,and they were divided into control group and observation group according to random number table,each of 80 cases.Based on conventional medical treatment,patients of control group received clopidogrel,while patients of observation group received xuezhikang tablets combined with clopidogrel;both groups continuously treated for 12 weeks.Clinical effect,blood lipids index(including TC,TG,LDL-C and HDL-C)and carotid atherosclerotic plaque related index(including plaque thickness,plaque size and CIMT)before and after treatment were compared between the two groups,and incidence of adverse reactions was observed.Results Clinical effect of observation group was statistically significantly better than that of control group(P0.05);after treatment,serum levels of TC,TG and LDL-C of observation group were statistically significantly lower than those of control group,while serum HDL-C level of observation group was statistically significantly higher than that of control group(P0.05),while plaque thickness,plaque size and CIMT of observation group was statistically significantly thinner or smaller than that of control group after treatment(P0.05).Conclusion Xuezhikang tablets combined with clopidogrel has certain clinical effect in treating unstable angina pectoris patients complicated with atherosclerosis,can effectively adjust the blood lipid metabolism and delay the carotid atherosclerotic plaque progression,and is relatively safe.%目的 分析血脂康片联合氯吡格雷治疗不稳定型心绞痛(UAP)伴动脉粥样硬化的临床疗效及安全性.方法 选取2014年6月-2015年6月陕西省核工业二一五医院收治的UAP伴动脉粥样硬化患者160例,采用随机数字表法分为对照组与观察组,每组80例.在常规药物治疗基础上,对照组患者予以氯吡格雷治疗,观察组患者予以血脂康片联合氯吡格雷治疗;两组患者均连续治疗12周.比较两组患者临床疗效、治疗前后血脂指标〔总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)〕及颈动脉粥样硬化斑块情况〔斑块厚度、斑块面积、颈动脉内膜中膜厚度(CIMT)〕,并观察两组患者治疗期间不良反应发生情况.结果 观察组患者临床疗效优于对照组(P0.05);治疗后观察组患者血清TC、TG、LDL-C水平低于对照组,血清HDL-C水平高于对照组(P0.05);治疗后观察组患者斑块厚度、斑块面积、CIMT小于对照组(P0.05).结论 血脂康片联合氯吡格雷治疗UAP伴动脉粥样硬化的临床疗效确切,可有效改善血脂代谢,延缓颈动脉粥样硬化斑块进展,且安全性较高.